titanium silicide (TS-1)

09/01/2006 - "This shows that TS-1 and CDDP may have potent therapeutic efficacy in advanced gastric cancer patients. "
05/01/2002 - "The current case suggests that TS-1 may have a potent therapeutic efficacy in cases of advanced gastric cancer."
01/01/2001 - "The current case suggests that TS-1 may have a potent therapeutic efficacy in advanced gastric cancer patients."
05/01/2005 - "Combination of TXL and TS-1 is expected to show good therapeutic efficacy and improve patients' QOL in patients with gastric cancer associated with peritoneal dissemination."
12/01/2003 - "Concurrent chemoradiation is feasible and seems to offer good results for recurrent gastric cancers resistant to TS-1."

08/01/2002 - "It was confirmed histopathologically that TS-1 was effective against the primary sites and lymph node metastasis. "
12/01/2012 - "Postoperatively, TS-1 administration was given for Virchow lymph node metastasis, which disappeared within 2 years and TS-1 was stopped. "
11/01/2006 - "Four months later, lung metastases were found, thus, he was administered TS-1. "
11/01/2006 - "As this patient underwent TS-1 treatment, sizes of multiple liver metastases and the blood concentration level of CEA were gradually reduced, and the reductive rate of the former was more than 90% and the level of the latter fell to a normal range after 12 courses of TS 1 treatment. "
08/01/2006 - "The patient with liver metastasis was treated using TS-1, and CT-scan showed a remarkable decrease (PR) in the metastatic lesion. "

02/01/2005 - "The efficacy of new anti-cancer drugs such as TS-1 system was revealed in a controlled study by comparing treatment with non-treatment groups. "
03/01/2015 - "After TS-1 treatment, the multiple tumors were no longer detectable, and the primary tumor did not increase in size for 4 years. "
11/01/2014 - "The cancer was unresectable, and chemoradiotherapy (CRT) with TS-1 was initiated in June 2010, and a partial response (PR) was observed. "
11/01/2014 - "One patient with a T3 tumor received oral TS-1 during RT because of advanced age. "
09/01/2014 - "We report a 49-year-old Japanese female with a large gastric tumor and protein-losing gastroenteropathy successfully treated with neoadjuvant TS-1 combined with CDDP therapy. "

10/01/2003 - "Taken together it is reasonable to conclude that TS-1 is safe and effective for patients with locally advanced or recurrent gastric carcinoma in an ambulatory setting, and is promising as a first line treatment in the general hospital."
10/01/2001 - "In the present study, we demonstrate the treatment results of TS-1 on 22 gastric carcinoma patients (15 far advanced and 7 recurrent patients) from June 1999 to December 2000. "
01/01/2013 - "This is the first reported case of relapsed cervicomediastinal lymph node carcinoma with an unknown primary site treated by TS-1 alone. "
01/01/2013 - "We report here the case of a patient successfully treated with TS-1 alone after the relapse of cervicomediastinal lymph node carcinoma with an unknown primary site. "
01/01/2013 - "Relapsed cervicomediastinal lymph node carcinoma with an unknown primary site treated with TS-1 alone: a case report."

12/01/2004 - "Chemoradiotherapy using TS-1 and weekly CDDP revealed their efficacy for esophageal cancer."
02/01/2005 - "This combined chemotherapy consisting of TS-1 and CDDP may prove effective for treating recurrent cases of esophageal cancer."
02/01/2004 - "TS-1 and CDDP therapy combined with radiotherapy appears to be effective in treating thoracic esophageal cancer."
03/01/2007 - "[Recurrent esophageal cancer with complete response to TS-1 chemotherapy]."
02/01/2004 - "Combined chemotherapy of TS-1 and CDDP with radiotherapy can be effective for advanced esophageal cancer."